ABX-464
- Generic Name
- ABX-464
- Drug Type
- Small Molecule
- Chemical Formula
- C16H10ClF3N2O
- CAS Number
- 1258453-75-6
- Unique Ingredient Identifier
- 26RU378B9V
- Background
ABX-464 is under investigation in clinical trial NCT03905109 (Safety Evaluation of ABX464 in Patients With Moderate to Severe Active Crohn's Disease).
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- Conditions
- Moderately to Severely Active Crohn Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 212
- Registration Number
- NCT06456593
- Locations
- 🇵🇱
Centrum Medyczne Plejady, Kraków, Poland
🇺🇸IMC Gulf Coast Gastroenterology, PC, Fairhope, Alabama, United States
🇺🇸Scottsdale Gastroenterology Specialists, Scottsdale, Arizona, United States
ABTECT - Maintenance
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 1050
- Registration Number
- NCT05535946
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Wexner Medical Center, Columbus, Ohio, United States
🇺🇸Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 612
- Registration Number
- NCT05507203
- Locations
- 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸Biopharma Informatic, LLC, Houston, Texas, United States
🇺🇸MedOne Clinical Research LLC, Miami, Florida, United States
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 612
- Registration Number
- NCT05507216
- Locations
- 🇺🇸
Ocala GI Research, Ocala, Florida, United States
🇺🇸Sarkis Clinical Trials - Parent, Ocala, Florida, United States
🇺🇸Iowa Digestive Disease Center, Clive, Iowa, United States
Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 203
- Registration Number
- NCT05177835
- Locations
- 🇵🇱
Centrum Medyczne Plejady, Kraków, Poland
🇧🇪UZ Leuven, Leuven, Belgium
🇵🇱Trialmed CRS, Piotrkow Trybunalski, Poland
Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 59
- Registration Number
- NCT05121714
- Locations
- 🇬🇧
Simbec-Orion, Merthyr Tydfil, United Kingdom
Safety and Pharmacokinetics Study in Healthy Japanese Volunteers
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 48
- Registration Number
- NCT05032560
- Locations
- 🇯🇵
Medical Corporation Heishinkai OPHAC Hospital, Osaka-shi, Osaka, Japan
ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 509
- Registration Number
- NCT04393038
- Locations
- 🇩🇪
Universitätsmedizin Mannheim Ruprecht-Karls-Universität Heid, Mannheim, Baden-Württemberg, Germany
🇧🇷Instituto Nacional de Infectologia Evandro Chagas - FIOCRUZ Rio de Janeiro, Rio De Janeiro, Brazil
🇫🇷Hôpital Saint-Antoine, Paris, France
Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 40
- Registration Number
- NCT04049448
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
🇧🇪UZ Gent, Gent, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Abivax S.A.
- Target Recruit Count
- 217
- Registration Number
- NCT04023396
- Locations
- 🇩🇪
Medizinische Hochschule Hannover, Hanover, Germany
🇦🇹AKH - Medizinische Universität Wien, Vienna, Austria
🇧🇾Gomel Regional Clinical Hospital, Gomel, Belarus
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.